Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (3128)	6/1/1999 12:57:00 PM
From: AJAG	Read Replies (1) \| Respond to of 10280

I find the market's muted reaction to today's great news very surprising. The drug involved in today's deal , Zyrtec, is very hot and is expected to be a billion dollar drug this year. Sepracor's improved version is already in Phase 3 clinical trials in Europe. THIS NEWS IS MUCH MORE SIGNIFICANT THAT THE JOHNSON & JOHNSON DECISION ON HISMANAL. The current version of Hismanal had sales of 100 million last year, an also-ran in the allergy market. I guess a lot of the traders and money managers that control Big Money must still be on the beach. I don't even recall the Zyrtec drug being discussed in the Sepracor annual report.